A noninvasive heart imaging scan may help identify cardiac sarcoidosis patients at risk of worse clinical outcomes, according to a study. A value of 42% or lower in left ventricular ejection fraction, or LVEF, a measure of how much blood is being pumped out of the heart’s left ventricle…
In Finland, only 2% of sarcoidosis patients without symptoms of eye involvement indeed had ocular sarcoidosis, suggesting that routine eye examinations are not needed in the Finnish patient population. But as the frequency of ocular sarcoidosis varies considerably among people with sarcoidosis worldwide, “more studies are needed to…
About six months with Acthar Gel were associated with greater therapeutic benefits than a placebo in people with pulmonary sarcoidosis receiving standard-of-care therapies, including glucocorticoids, data from a Phase 4 trial show. The benefits were sustained in those who continued treatment in an extension phase and became evident…
After the success of its virtual event last year, the Foundation for Sarcoidosis Research (FSR) is gearing up to once again host an online summit for all those impacted by sarcoidosis. The “Third Annual Global Virtual Patient Summit: Unveiling Possibilities” is set for July 30–31. Billed as the…
The Foundation for Sarcoidosis Research (FSR) has launched the FSR Global Sarcoidosis Clinic Alliance, a hub of clinics and hospitals around the world to advance care and research in sarcoidosis. Through engagement and education of both patients and clinicians, the initiative seeks to improve the lives of people with…
A recent technique for collecting lung tissue for analysis, called transbronchial lung cryobiopsy, is better than more conventional methods for a definitive sarcoidosis diagnosis, according to a German study. The study, “Diagnostic Yield of Transbronchial Lung Cryobiopsy Compared to Transbronchial Forceps Biopsy in Patients with Sarcoidosis in a…
A recent episode of TV’s “Behind the Mystery” shared the journey of a sarcoidosis patient from diagnosis to treatment as a way to raise awareness of the emotional and medical challenges of living with this complex condition. The episode, shown on Lifetime on Dec. 6 and again Dec. 14,…
People with autoimmune diseases such as sarcoidosis are not at higher risk of worse outcomes following lung or heart-lung transplants compared with people without such diseases, a new single-center study shows. The findings that autoimmune patients fare as well as others following such transplants refute the long standard approach…
A Phase 2 clinical trial is recruiting adults with chronic pulmonary sarcoidosis to investigate the safety and therapeutic potential of CMK389 in improving lung function. CMK389 is an investigational therapy, developed by Novartis, for the treatment of pulmonary sarcoidosis and atopic dermatitis. It was designed to inhibit interleukin 18,…
A Phase 2 clinical trial investigating the inhaled sarcoidosis therapy aviptadil — also known as RLF-100, and designed to block inflammation in the lungs — has been cleared to start in Germany. The clearance by the German medical regulatory authority Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) was given to…
Get regular updates to your inbox.